Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs (CROSBI ID 324379)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Rešetar Maslov, Dina ; Farkaš, Vladimir ; Rubić, Ivana ; Kuleš, Josipa ; Beletić, Anđelo ; Beer Ljubić, Blanka ; Šmit, Iva ; Mrljak, Vladimir ; Torti, Marin Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs // International journal of molecular sciences, 24 (2023), 8; 7142, 25. doi: 10.3390/ijms24087142

Podaci o odgovornosti

Rešetar Maslov, Dina ; Farkaš, Vladimir ; Rubić, Ivana ; Kuleš, Josipa ; Beletić, Anđelo ; Beer Ljubić, Blanka ; Šmit, Iva ; Mrljak, Vladimir ; Torti, Marin

engleski

Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs

Canine myxomatous mitral valve disease (MMVD) is similar to Barlow’s form of MMVD in humans. These valvulopathies are complex, with varying speeds of progression. We hypothesized that the relative abundances of serum proteins would help identify the consecutive MMVD stages and discover new disease pathways on a systemic level. To identify distinction-contributing protein panels for disease onset and progression, we compared the proteomic profiles of serum from healthy dogs and dogs with different stages of naturally occurring MMVD. Dogs were divided into experimental groups on the basis of the left-atrium-to-aorta ratio and normalized left ventricular internal dimension in diastole values. Serum was collected from healthy (N = 12) dogs, dogs diagnosed with MMVD in stages B1 (N = 13) and B2 (N = 12) (asymptomatic), and dogs diagnosed with MMVD in chronic stage C (N = 13) (symptomatic). Serum biochemistry and selected ELISAs (galectin-3, suppression of tumorigenicity, and asymmetric dimethylarginine) were performed. Liquid chromatography–mass spectrometry (LC–MS), tandem mass tag (TMT) quantitative proteomics, and statistical and bioinformatics analysis were employed. Most of the 21 serum proteins with significantly different abundances between experimental groups (p < 0.05, FDR ˂ 0.05) were classified as matrix metalloproteinases, protease inhibitors, scaffold/adaptor proteins, complement components, anticoagulants, cytokine, and chaperone. LC–MS TMT proteomics results obtained for haptoglobin, clusterin, and peptidase D were further validated analytically. Canine MMVD stages, including, for the first time, asymptomatic B1 and B2 stages, were successfully distinguished in dogs with the disease and healthy dogs on the basis of the relative abundances of a panel of specific serum proteins. Most proteins with significantly different abundances were involved in immune and inflammatory pathways. Their role in structural remodeling and progression of canine MMVD must be further investigated. Further research is needed to confirm the resemblance/difference with human MMVD. Proteomics data are available via ProteomeXchange with the unique dataset identifier PXD038475.

myxomatous mitral valve disease ; proteomics ; dogs ; innate immune system ; inflammation ; echocardiography

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

24 (8)

2023.

7142

25

objavljeno

1422-0067

10.3390/ijms24087142

Trošak objave rada u otvorenom pristupu

APC

Povezanost rada

Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Interdisciplinarne biotehničke znanosti, Interdisciplinarne prirodne znanosti, Kemija, Kliničke medicinske znanosti

Poveznice
Indeksiranost